The prevalence of cardiovascular disease (CVD) in antiphospholipid syndrome (APS) varies from one series to another depending on the definition of CVD and tools used for its detection. Atherosclerosis, the usual cause of CVD, starts when the endothelium becomes damaged and is considered to be an autoimmune-inflammatory disease. The excessive cardiovascular events observed in patients with APS are not fully explained by traditional risk factors. Therefore, several novel risk factors contribute to the development of premature CVD and accelerated vascular damage in those patients. Herein, the significance and outcomes of CVD in APS are reviewed.
Perez-Sanchez C, Barbarroja N, Messineo S, et al. Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus. Ann Rheum Dis. Epub ahead of print 11 March 2014.
2.
ShoenfeldYGerliRDoriaA. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation2005; 112: 3337–3347.
3.
Amaya-AmayaJSarmiento-MonroyJCRojas-VillarragaACardiovascular involvement in autoimmune diseases. In: AnayaJMShoenfeldYRojas-VillarragaALevyRACerveraR (eds). Autoimmunity: From bench to bedside, Bogotá, Colombia: Universidad del Rosario, 2013, pp. 653–682.
4.
GiannakopoulosBKrilisSAGiannakopoulosBK. The pathogenesis of the antiphospholipid syndrome. N Engl J Med2013; 368: 1033–1044.
5.
ShortellCKOurielKGreenRMCondemiJJDeWeeseJA. Vascular disease in the antiphospholipid syndrome: A comparison with the patient population with atherosclerosis. J Vasc Surg1992; 15: 158–165.
6.
VaaralaOMänttäriMManninenV. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation1995; 91: 23–27.
7.
ComarmondCCacoubP. Antiphospholipid syndrome: From pathogenesis to novel immunomodulatory therapies. Autoimmun Rev2013; 12: 752–757.
CerveraR. Coronary and valvular syndromes and antiphospholipid antibodies. Thromb Res2004; 114: 501–507.
10.
MedinaGGutiérrez-MorenoALVera-LastraOSaavedraMAJaraLJ. Prevalence of metabolic syndrome in primary antiphospholipid syndrome patients. Autoimmun Rev2011; 10: 214–217.
11.
BeliznaCCRichardVThuillezCLévesqueHShoenfeldY. Insights into atherosclerosis therapy in antiphospholipid syndrome. Autoimmun Rev2007; 7: 46–51.
12.
VeresKLakosGKerényiA. Antiphospholipid antibodies in acute coronary syndrome. Lupus2004; 13: 423–427.
13.
SoltészPVeresKLakosGKissEMuszbekLSzegediG. Evaluation of clinical and laboratory features of antiphospholipid syndrome: A retrospective study of 637 patients. Lupus2003; 12: 302–307.
14.
ErkanDAguiarCLAndradeD. 14th International Congress on Antiphospholipid Antibodies: Task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev2014; 13: 685–696.
